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Kindlin-3 (K3)–mediated integrin adhesion controls homing and
bone marrow (BM) retention of normal hematopoietic cells. How-
ever, the role of K3 in leukemic stem cell (LSC) retention and
growth in the remodeled tumor-promoting BM is unclear. We re-
port that loss of K3 in a mouse model of chronic myeloid leukemia
(CML) triggers the release of LSCs from the BM into the circulation
and impairs their retention, proliferation, and survival in second-
ary organs, which curbs CML development, progression, and met-
astatic dissemination. We found de novo expression of cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) on CML-LSCs but not
normal hematopoietic stem cells and this enabled us to specifically
deplete K3 with a CTLA-4–binding RNA aptamer linked to a K3-
siRNA (small interfering RNA) in CTLA-4+ LSCs in vivo, which mo-
bilized LSCs in the BM, induced disease remission, and prolonged
survival of mice with CML. Thus, disrupting interactions of LSCs
with the BM environment is a promising strategy to halt the
disease-inducing and relapse potential of LSCs.
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Chronic myeloid leukemia (CML) is a clonal, hematopoieticmalignancy of the myeloid lineage caused by the transfor-
mation of a hematopoietic stem cell (HSC) into a disease-
initiating leukemic stem cell (LSC). The course of CML typically
progresses from a chronic phase (CP-CML) characterized by the
accumulation of neutrophils and LSCs in the bone marrow (BM)
and peripheral blood (PB) and the remodeling of the BM micro-
environment into a malignant BM niche to a fatal blast crisis
(BC-CML) characterized by the rapid expansion of differentiation-
arrested myeloid or lymphoid precursor cells (1–8). In almost all
cases of CML, the malignant transformation results from a char-
acteristic reciprocal translocation between chromosomes 9 and 22
in HSCs, which generates the breakpoint cluster region–Abelson
(BCR-ABL) fusion gene. Depending on the BCR breaking point,
the chimeric gene is translated into the p190, p210 (most com-
mon), or p230 BCR-ABL oncoprotein (9, 10). The underlying
mechanism(s) for the CP-CML–to–BC-CML transition is not
known. It is surmised, however, that secondary genetic and/or
epigenetic changes in leukemic cells lead to the formation and
expansion of leukemic clones with increasingly malignant charac-
teristics (2, 11).
CML is treated with ABL tyrosine kinase inhibitors (TKIs) such
as imatinib, which block proliferation of leukemic cells and prevent
the accumulation of neutrophils in the PB and BM (12) and the
onset of a BC-CML (13–16). Although treatment of CML with
TKIs often leads to complete remission and normal life expectancy,
a drawback of the inhibitor treatment is the poor effect on a
subpopulation of Bcr-Abl–positive self-renewing LSCs protected
within the leukemic BM niche (4, 17–20), resulting in a lifelong
treatment requirement. Moreover, around 16% of imatinib-treated
patients develop an intolerance against ABL TKIs and around
10% acquire mutations in the BCR-ABL fusion gene, resulting in
therapy resistance (16).
Hematopoietic stem and progenitor cells (HSPCs) receive bio-
chemical and biophysical cues from the BM microenvironment
that promote retention, self-renewal, regeneration, and differen-
tiation (3, 4). The positioning and retention of HSPCs within the
BM critically depend on integrin-mediated adhesion to extracel-
lular matrix (ECM) proteins such as osteopontin, fibronectin (FN),
collagens, laminins, and cell surface-presented ligands such as
vascular cell adhesion protein 1 (VCAM-1) or intercellular adhe-
sion molecule 1 (ICAM-1) (21–27). We have shown that both in
mice and humans, BM retention and survival of HSPCs depend on
Kindlin-3 (K3) (28), which is expressed in all hematopoietic cells
(29). K3 is an essential integrin-binding and -activating adaptor
protein (30), whose loss leads to dysfunctional erythrocytes,
platelets, and immune effector cells collectively termed leukocyte
adhesion deficiency type III (LAD-III) in humans (31–36).
Since LSCs remodel the cellular and ECM composition of BM
niches, which in turn further fuel LSC malignancy (3–8), we in-
vestigated in a murine CML model if and how K3 loss influences
the association of LSCs with the BM microenvironment and the
lifespan of leukemic mice, and whether K3 depletion can be
utilized as a novel treatment strategy for CML. Our findings on
the involvement of K3 in CML induction, development, and
intervention are discussed.
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Kindlin-3 Retains LSCs in the BM and Promotes CML Development. To
test the function of K3 for LSCs, we established a mouse strain in
which the expression of the Bcr-Abl oncogene can be conditionally
induced and the floxed Fermt3 gene can be conditionally disrupted
in HSPCs (28, 37). To obtain this mouse strain, we intercrossed
mice carrying the following transgenes: the stem cell leukemia-
driven tetracycline-controlled transactivator (Scl-tTA), a tetracycline-
responsive element-driven Bcr-Abl (Tre-Bcr-Abl), a tamoxifen-
regulated and ubiquitously expressed Cre (Rosa26-Cre-ERT2),
and a floxed Fermt3 (K3fl/fl) on a C57BL/6 CD45.2+ background
(termed BAcondK3cond). To avoid anemia, dysfunctional effector
cells, and impaired BM retention of HSPCs in Fermt3-null mice
(28, 31–33, 38), we generated mixed BM chimeras by transplanting
CD45.2+ BAcondK3cond BM cells from tetracycline-treated donor
animals and wild-type (WT) BM cells from CD45.2+CD45.1+ F1
donor animals in a 1:1 ratio into lethally irradiated WT congenic
CD45.1+ C57BL/6.SJL recipient mice. The resulting mixed BM
chimeras were further treated with tetracycline to suppress Bcr-Abl
expression in BAcondK3cond (CD45.2+) cell populations. Once the
mixed hematopoietic system was successfully established 8 wk post
transplantation, we administered tamoxifen to knockout the
Fermt3 gene (K3KO), or oil to retain expression of the floxed K3
gene (K3WT), followed by the withdrawal of tetracycline and the
induction of Bcr-Abl expression 2 wk later. Using this strategy,
we finally obtained mixed BM chimeric animals containing WT
together with either BA+K3WT or BA+K3KO hematopoietic cells
(Fig. 1A). To indicate that the BA+K3WT (CD45.2+) and the
BA+K3KO (CD45.2+) chimeras were competitively transplanted
with WT BM (CD45.2+CD45.1+) cells, we termed them
BA+K3WT and BA+K3KO mixed chimeras, respectively. Western
blots verified the functionality of our transgenes and confirmed
K3 protein loss and induction of Bcr-Abl expression in CD45.2+
splenocytes from mixed chimeras upon tamoxifen treatment and
withdrawal of tetracycline. CD45.2+ splenocytes isolated from
BA+K3KO chimeras did not express Bcr-Abl oncoprotein, sug-
gesting that they originate from nontransformed HSCs (Fig. 1B;
see also below Fig. 5).
Next, we monitored the disease onset by determining the ratio of
BA+K3WT or BA+K3KO (CD45.2+) and WT (CD45.2+/CD45.1+)
leukocytes in 2-wk intervals in the PB using flow cytometry. Al-
though BAcondK3cond (CD45.2+) and WT (CD45.2+CD45.1+) BM
cells were transplanted in a 1:1 ratio, we observed a 2:1 ratio of
CD45.2+:CD45.2+CD45.1+ cells 10 wk after transplantation (time
point 0) in BA+K3WT and BA+K3KOmixed chimeras. In BA+K3WT
mixed chimeras the percentage of CD45.2+ BA+K3WT cells steadily
increased and the CD45.2+CD45.1+ WT cells decreased in the PB,
indicating that normal hematopoiesis is outcompeted by malignant
hematopoiesis, which together with the death of the mice is a typical
hallmark of CML progression (Fig. 1C and SI Appendix, Fig. S1A).
In BA+K3KO mixed chimeras, the percentage of CD45.2+
BA+K3KO cells transiently increased in the PB 2 wk after tetracy-
cline withdrawal (Fig. 1C), which was due to an elevated release of
BA+K3KO B220+ B cells and Gr1hi/Mac1+ neutrophils, but not
T cells, into the PB (Fig. 1 D and E and SI Appendix, Fig. S1 B and
C). The BA+K3KO cell numbers began to decrease at around 4 wk
after tetracycline withdrawal and reached a plateau 8 to 10 wk later
(Fig. 1C), while CD45.2+CD45.1+ WT cell numbers rose and
reached normal levels 10 wk after tetracycline withdrawal (SI Ap-
pendix, Fig. S1A). The CD45.2+ Gr1hi/Mac1+ neutrophils also rose
6 wk post tetracycline withdrawal in BA+K3WT mixed chimeras,
whereas CD45.2+ Gr1hi/Mac1+ neutrophils remained at normal
levels for more than 14 wk in BA+K3KO mixed chimeras and began
slowly rising ∼19 wk after tetracycline withdrawal (Fig. 1 F and G).
The significantly lower numbers of CD45.2+ Gr1hi/Mac1+
neutrophils in the BM of BA+K3KO mixed chimeras (Fig. 1H)
were associated with a reduction of lineage−Sca-1+c-kit+ (LSK)
cells. To define the LSK subpopulation(s) affected by K3 loss, we
used the SLAM family markers CD150 and CD48 to define which
LSK subpopulations were affected by K3 loss. Flow cytometry
revealed that the LSK CD150+CD48− population highly enriched
with HSCs/LSCs (7, 39) and LSK CD150+CD48+ and LSK
CD150−CD48+ populations enriched with hematopoietic progeni-
tor cells (HPCs) (39) were significantly reduced in the BM of
BA+K3KO mixed chimeras (Fig. 1I). The reduction of the different
LSK populations in the BM of BA+K3KO mixed chimeras resulted
in a decline of the CD45.2+ BA+K3KO LSK fraction (Fig. 1J), which
was associated with a diminished proliferation (Fig. 1K) and release
into the PB as early as 2 wk after tetracycline withdrawal (Fig. 1L).
In line with the CD45.2+ BA+K3KO LSK cell release into the PB,
PB samples from BA+K3KO mixed chimeras showed an elevated
colony formation potential in colony-forming unit-granulocyte,
monocyte (CFU-GM) assays (Fig. 1M). Short-term homing assays
indicated that the BM entry of CD45.2+ BA+K3KO LSK
CD150+CD48− cells was reduced (SI Appendix, Fig. S1D), whereas
spleen infiltration was unaffected (SI Appendix, Fig. S1E). Interest-
ingly, however, CD45.2+ BA+K3KO LSK CD150+CD48− cells did
not expand in spleens of mixed BM chimeras for up to 6 wk post
leukemia induction (SI Appendix, Fig. S1F). In contrast to the pro-
nounced defects upon K3 loss, BA+K3WT mixed chimeras con-
tained similar numbers of highly proliferative CD45.2+ BA+K3WT
and CD45.2+CD45.1+ WT LSK cells in the BM and exhibited low
LSK cell numbers in the PB, rare colony formation potential in
CFU-GM assays, high BM homing rates, and increased spleen
cellularity (Fig. 1 J–M and SI Appendix, Fig. S1 D–F). Furthermore,
the few circulating CD45.2+ BA+K3WT LSK cells were prone to
apoptosis, which was more pronounced in CD45.2+ BA+K3KO LSK
cells (Fig. 1N). These findings indicate that K3 is essential for LSC
retention in protective BM niches as well as secondary organs such
as the spleen.
Kindlin-3 Loss Reduces CML Mortality. Based on our findings, K3
loss should have a distinct impact on the survival of BA+K3KO
mixed chimeras. Indeed, Kaplan–Meier survival analysis revealed a
profound lifespan extension of BA+K3KO mixed chimeras, which
survived on average 189 d as compared with 64 d of BA+K3WT
mixed chimeras (Fig. 2A). Moribund BA+K3WT mixed chimeras
suffered from several characteristic end-stage hematological ab-
normalities (16) including anemia, hemorrhage, and leukemic cell
infiltration in the lung and liver, while BA+K3KO mixed chimeras
developed none of the symptoms, indicating that K3 enables CML
development. Despite efficient Cre-mediated Fermt3 deletion, a few
BA+K3KO mixed chimeras showed a shortened lifespan, which was
not due to CML but rather caused by the poorer engraftment ef-
ficiency of CD45.2+CD45.1+ WT cells.
To investigate whether loss of K3 is also able to stop or retard
full-blown CML, we first withdrew tetracycline to generate
BA+K3cond mixed chimeras and upon CML development (>20%
PB neutrophils; termed leukemic mice) administered tamoxifen
to delete the Fermt3 gene. Control cohorts received oil to retain
K3 expression (Fig. 2B). Whereas oil-treated BA+K3WT mice
had enlarged spleens, leukemic cell infiltrations into the spleen,
and survived on average 65 d after tetracycline withdrawal, more
than 75% of the tamoxifen-treated BA+K3KO mixed chimeras
were still alive with normal spleen size and cellularity at 110 d
post tetracycline withdrawal (Fig. 2C). These findings strongly
suggest that loss of K3-mediated integrin adhesion delays CML
development as well as progression in vivo.
Loss of Kindlin-3 Attenuates the Blast Crisis Induced by Bcr-Abl+
Myeloblasts. The profound expansion of mature myeloid cells
and leukemic organ infiltration results in the death of Scl-tTA/
Tre-Bcr-Abl mice before the onset of a myeloid blast crisis (7,
37). Therefore, we used our recently established 32D blast cell
crisis model (40) to investigate whether K3 expression also


































Fig. 1. K3 loss mobilizes LSCs. (A) BA+K3WT and BA+K3KO mixed chimeras generated by transferring BM cells carrying a conditional, HSPC-inducible, and
tetracycline-controlled Bcr-Abl (BA) transgene and a conditional, tamoxifen-inducible, Fermt3-null allele wild type mixed with WT BM cells into lethally ir-
radiated recipient mice. The congenic CD45.1 and CD45.2 surface receptors are used to distinguish transgenic, WT, and host cells. Tamoxifen or oil were
administered orally (p.o.). (B) Bcr-Abl, c-Abl, K3, and tubulin protein expression in CD45.2+ splenocytes. (C) Ratio between transgenic (CD45.2+) and WT
(CD45.2+CD45.1+) leukocytes in the PB of BA+K3WT (n ≥ 8) and BA+K3KO (n ≥ 11) mixed chimeras. Statistics by multiple t test, two-sided. (D and E) Numbers of
B220+ B cellc (D) and Gr1high/Mac1+ neutrophils (E) per microliter of PB determined 2 wk after leukemia induction (n = 18). Statistics by Mann–Whitney U test
(D) and unpaired t test, two-sided (E). (F and G) Percentage of PB neutrophils (F) and ratio (G) between transgenic (CD45.2+) and WT (CD45.2+CD45.1+) PB
neutrophils in BA+K3WT (n ≥ 8), BA+K3KO (n ≥ 11), and BA−K3WT (n = 7) chimeras at the indicated time points after tetracycline withdrawal. Statistics by
multiple t test, two-sided. (H) Ratio between transgenic (CD45.2+) and WT (CD45.2+CD45.1+) BM neutrophils in BA+K3WT and BA+K3KO mixed chimeras 6 wk
after tetracycline withdrawal (n ≥ 7). Statistics by unpaired t test, two-sided. (I) Numbers of LSK, LSK CD150−CD48+, LSK CD150+CD48+, and LSK CD150+CD48−
cells per femur in BA+K3WT and BA+K3KO mixed chimeras 6 wk off tetracycline (n ≥ 7). Statistics by unpaired t test, two-sided. (J) Ratio between transgenic
(CD45.2+) and WT (CD45.2+CD45.1+) LSK cells in the BM of BA+K3WT and BA+K3KO mixed chimeras 6 wk after tetracycline withdrawal (n ≥ 7). Statistics by
unpaired t test, two-sided. (K) Percentage of BrdU+ (bromodeoxyuridine-positive) transgenic (CD45.2+) LSK cells in the BM of BA+K3WT and BA+K3KO mixed
chimeras 6 wk off tetracycline (n = 5). Statistics by unpaired t test, two-sided. (L) Number of LSK cells per microliter of PB in BA+K3WT and BA+K3KO mixed
chimeras 2 wk after tetracycline withdrawal (n ≥ 16). Statistics by unpaired t test, two-sided. (M) Frequency of GM-CFUs in 50 μL PB of BA+K3WT and BA+K3KO
mixed chimeras 2 wk off tetracycline after 13 d of culture (n ≥ 5). Statistics by Mann–Whitney U test, two-sided. (N) Percentage of apoptotic Annexin-V+ PB
LSK cells in BA+K3WT and BA+K3KO mixed chimeras 2 wk after tetracycline withdrawal (n ≥ 7). Statistics by unpaired t test, two-sided. Data are shown as
mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001.



























influences the course of a blast-like CML in vivo. To this end, we
generated red fluorescent protein (RFP)-tagged Bcr-Abl–expressing
murine 32D myeloblast cells (BA+K3+), produced BA+K3− cells by
disrupting the K3-encoding Fermt3 gene using CRISPR-Cas9 tech-
nology (Fig. 3A), injected RFP+ BA+K3+ or RFP+ BA+K3− cells
into nonirradiated syngeneic C3H/HeOuJ mice, and monitored their
survival. BA+K3+ cell-injected recipient mice died ∼12 d after in-
jection, whereas BA+K3− cell-treated mice survived ∼20 d (Fig. 3B).
At 11 d post injection, spleen size and weight in BA+K3+ cell-
injected animals were increased and the splenic architecture was se-
verely damaged, which was neither observed in BA+K3− cell- nor
phosphate-buffered saline (PBS)-injected control mice (Fig. 3C and
SI Appendix, Fig. S2A). Blast cell infiltration and expansion in the
spleen, PB, and BM were determined by quantifying RFP+ BA+K3+
and BA+K3− cell numbers 6 and 11 d post injection. In line with
normal spleen size, RFP+ tumor cells were barely detectable in the
spleen and PB of BA+K3− cell-injected animals. The percentage of
RFP+ cells was ∼40% in the PB of BA+K3+ cell-injected mice,
which corresponds to an 83-fold higher absolute tumor load in
BA+K3+ compared with BA+K3− cell-injected animals (Fig. 3D and
E). RFP+ BA+K3+ cells were readily detectable in the BM 6 d after
injection and further increased 11 d post injection (Fig. 3 F andG). In
contrast, BA+K3− cells were barely detected in the BM 6 d post
injection (Fig. 3F) and increased 11 d after injection to a level that
was fivefold lower compared with BA+K3+ cell-injected animals
(Fig. 3G).
Despite the low numbers, BA+K3− cell proliferation was only
slightly reduced in the BM (Fig. 3H). To investigate whether
impaired homing contributes to the low BA+K3− cell numbers in
the BM, we mixed equal numbers of carboxyfluorescein succi-
nimidyl ester (CFSE)-labeled BA+K3− and CellTrace violet
(CTV)-labeled BA+K3+ cells or vice versa, injected them in-
tracardially into syngeneic, nonirradiated C3H/HeOuJ mice, and
quantified dye+ cells in the BM, PB, and spleen 3 h post injec-
tion. The experiments revealed significantly fewer BA+K3− cells
in the BM but similar numbers of BA+K3+ and BA+K3− cells in
the PB and spleen (Fig. 3I). In line with the decreased prolif-
eration of BA+K3− cells in the BM (Fig. 3H), they also under-
went fewer cell divisions in the PB (Fig. 3J) and were more prone
to apoptosis (Fig. 3K). Of note, cell-cycle progression, prolifer-
ation, and viability of in vitro cultured BA+K3− and BA+K3+
cells were alike, indicating that K3 modulates 32D cell prolif-
eration and survival in the in vivo environment but not when
propagated in vitro (SI Appendix, Fig. S2 B–D).
Bcr-Abl Amplifies Integrin Activity in a K3-Dependent Manner. To
investigate how K3 promotes the life-shortening blast phase of
Bcr-Abl–expressing 32D cells, we compared adhesion and mi-
gration of parental Bcr-Abl–negative (BA−K3+), BA+K3+, and
BA+K3− 32D cells (Fig. 4A). In plate and wash assays, BA+K3+
cells adhered significantly more strongly to FN, VCAM-1, and
ICAM-1 than parental BA−K3+ cells. Similarly, as reported for
erythroleukemia-type K562 cells (41), the enforced adhesion
caused by Bcr-Abl was abolished upon loss of K3 expression in
BA+K3− cells (Fig. 4B) and regained upon reexpression of the
human K3-encoding complementary DNA (BA+K3rescue; Fig. 4 A
and B). BA+K3+ cells also resisted shear forces of 2.5 dyn/cm2
significantly better than BA−K3+ and BA+K3− cells and arrested
on FN and VCAM-1 in an α5- and α4-integrin–dependent manner
(Fig. 4C and SI Appendix, Fig. S3A). The strong integrin-mediated
adhesion of BA+K3+ cells as well as the absent adhesion of
BA+K3− cells curbed migration toward a CXCL12 chemokine
gradient to background level (Fig. 4D). Bcr-Abl kinase inhibition
with imatinib partially restored the chemokine-induced migration
of BA+K3+, suggesting that the Bcr-Abl kinase activity strength-
ens adhesion and diminishes migration (Fig. 4D).
The enhanced adhesion of BA+K3+ to FN and VCAM-1 was
not due to an altered integrin cell-surface profile, which was
comparable to BA+K3− cells and only slightly changed when
compared with BA−K3+ cells (SI Appendix, Fig. S3B). However,
levels of β1-integrin activation-associated 9EG7 epitope were
elevated on BA+K3+ cells and reduced on BA+K3− cells
(Fig. 4E). Integrin activation requires binding of the adaptor
proteins Talin-1 and K3 to the cytoplasmic domain of β-integrins
(30), which were both up-regulated at the messenger RNA
(mRNA) as well as protein level in BA+K3+ cells. Of note, K3
mRNA levels were also elevated in human CML cells (SI Ap-
pendix, Fig. S3C) (42, 43). Interestingly, inhibition of the con-
stitutive Abl kinase activity of Bcr-Abl for 24 h with imatinib
reduced phosphorylation of the Bcr-Abl substrate CrkL and
normalized Talin-1 but not K3 levels, suggesting that Talin-1
expression is controlled by the Bcr-Abl kinase activity and K3
expression is controlled by the Bcr-Abl adaptor function (Fig. 4 F
and G).
Therapeutic Strategy to Target Kindlin-3 Specifically in LSCs. Our
findings suggested that depletion of K3 in LSCs might be a novel
strategy to combat CML. To deliver a K3-depleting agent, such
as a K3-siRNA (small interfering RNA), into LSCs, we first
searched for cell-surface proteins whose expression is absent on
normal HSPCs but induced on disease-initiating LSCs. Since
immune checkpoint molecules are frequently up-regulated or de
Fig. 2. Deletion of Fermt3 prolongs lifespan. (A) Kaplan–Meier survival
curve of BA+K3WT and BA+K3KO mixed chimeras treated orally (p.o.) with
tamoxifen before tetracycline withdrawal (n = 18). (B) BAcondK3cond mixed
chimeras first withdrawn from tetracycline (BA+) followed by tamoxifen
(K3KO) or oil (K3WT) treatment. (C) Kaplan–Meier survival curve of BA+K3WT
and BA+K3KO mixed chimeras treated with tamoxifen after tetracycline
withdrawal (n ≥ 12). Statistics by log-rank test. ***P < 0.001.


































novo expressed on transformed cells (44), we isolated LSK cells
from leukemic CD45.2+ Scl-tTA/Tre-Bcr-Abl mice (15 to 20%
neutrophils in the PB; termed BA+K3WT mice) and performed
qRT-PCR measurements of programmed cell death protein 1
(PD-1), programmed cell death 1 ligand 1 (PDL1) and ligand 2
(PDL2), lymphocyte-activation gene 3 (LAG3), T cell immuno-
globulin and mucin-domain containing 3 (TIM3), and cytotoxic
T lymphocyte-associated antigen 4 (CTLA-4). None of the im-
mune checkpoint molecules tested were expressed by wild-type
(BA−K3WT) LSK cells, whereas only CTLA-4 was detectable in
BA+K3WT LSK cells (Fig. 5 A and B and SI Appendix, Fig. S4A).
Flow cytometry revealed CTLA-4 protein expression on ∼6% of
the BA+K3WT LSK cells and on very few CTLA-4+ BA−K3WT
LSK cells, which—in light of the absent CTLA-4 mRNA ex-
pression by BA−K3WT LSK cells (Fig. 5 A and B)—likely rep-
resents a nonspecific staining signal (Fig. 5C). A refined analysis
identified CTLA-4+ leukemic cells in all HSPC subpopulations
(Fig. 5D). To confirm that the disease-initiating LSCs are enriched in
the CTLA-4+ HSC population, we engrafted 100 CD45.2+ LSK
CD150+CD48− CTLA-4+ or 100 CD45.2+ LSK CD150+CD48−
CTLA-4− cells from the BM of BA+K3WT mice into sublethally ir-
radiated CD45.1+ WT recipients and monitored PB donor cell repo-
pulation and CML development. Whereas the LSK CD150+CD48−
CTLA-4+ cells rapidly engrafted and induced a leukemic neutrophil
population in 10 out of 10 recipients, the LSK CD150+CD48− CTLA-
4− cells showed reduced repopulation potential and increased neu-
trophil numbers in only 3 out of 11 recipients (Fig. 5E and F), strongly
suggesting that the LSCs are enriched in the CTLA-4+ HSC pop-
ulation.
To transfer these findings into an in vivo CML treatment
protocol, we utilized the rapidly internalizing and recycling
CTLA-4 surface protein (45) as an LSC-specific anchor to de-
liver a specific and highly stable murine K3 (mK3)-siRNA linked
to a CTLA-4–binding RNA aptamer (46) (Fig. 5G and SI
Fig. 3. K3 promotes CML blast crisis. (A) Protein expression of RFP, Bcr-Abl, c-Abl, K3, and GAPDH by Bcr-Abl–expressing (BA+) 32D myeloblasts with or
without a Fermt3 gene deletion (K3+ or K3−). (B) Kaplan–Meier survival curve of syngeneic C3H/HeOuJ mice transplanted with either RFP+ BA+K3+ or RFP+
BA+K3− cells (n = 8). Statistics by log-rank test. (C–G) Engraftment parameters including spleen weights 11 d after transplantation (n ≥ 5) (C), RFP+ cells in
spleen (D), PB (E), and BM (F and G) at 11 d (D–F; n ≥ 9) or 6 d (G; n = 5) after transplantation. Statistics by one-way ANOVA, Tukey’s multiple-comparison test
(C), or unpaired t test, two-sided (D–G). (H) Percentage of BrdU+ 32D cells in the BM at day 11 after transplantation (n = 5). Statistics by unpaired t test, two-
sided. (I) Relative homing rates of CFSE- or CTV-labeled BA+K3+ or BA+K3− 32D cells in the spleen, PB, and BM 3 h after intracardial injection (n ≥ 7). Statistics
by paired t test, two-sided. (J and K) PB 32D (J) cell divisions and (K) cell viability 3 h post injection (n ≥ 5). Statistics by paired t test, two-sided. Data are shown
as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001.



























Appendix, Fig. S4 B–D). The high siRNA stability was achieved
by methylating the first three ribonucleotides of the mK3-siRNA,
which efficiently decreased K3 mRNA and protein in nucleofected
BA+K3+ 32D cells (SI Appendix, Fig. S4 B–D). The treatment of
CTLA-4–expressing BA+K3+ 32D cells with the CTLA-4
aptamer-tagged mK3-siRNA also reduced K3 mRNA more than
15-fold when compared with cells treated with CTLA-4 aptamer-
tagged scrambled control-siRNA (scr; SI Appendix, Fig. S4E).
In line with the expression of CTLA-4 on ∼10% BA+K3WT
LSK CD150+ cells (Fig. 5D), the CTLA-4 aptamer bound to 5 to
10% of BA+K3WT but was unable to bind to BA−K3WT LSK
CD150+ cells in vitro (Fig. 5H). A daily short-term treatment of
BA+K3WT mice with the CTLA-4 aptamer-tagged mK3-siRNA
for 4 consecutive days efficiently decreased the K3 mRNA in
CTLA-4+ LSK cells (Fig. 5I). Impressively, two cycles of five
daily injections of the CTLA-4 aptamer-tagged mK3-siRNA over
the course of 14 d normalized neutrophil counts in the PB and
spleen size and dramatically extended the lifespan of BA+K3WT
mice compared with animals treated with CTLA-4 aptamer-
tagged scrambled control-siRNA (Fig. 5 J and K and SI Appen-
dix, Fig. S4 F and G). Moreover, retreatment of BA+K3WT mice
suffering from a relapse, caused by de novo Bcr-Abl expression
and/or treatment-evading LSCs, resulted in prolonged remis-
sions (Fig. 5L). Importantly, the clinical benefits of the CTLA-4
aptamer-tagged mK3-siRNA treatment were due to the K3-
siRNA, as treatments with CTLA-4 aptamer-tagged scrambled
control-siRNA or anti–CTLA-4 blocking antibodies did not im-
prove elevated neutrophil counts in the PB, CML course or ac-
tivity, and numbers of T effector cells in leukemic BA+K3WT
mice (SI Appendix, Fig. S4 H–J).
The reduced CTLA-4+ LSK CD150+CD48− cell numbers in
the BM (Fig. 5M) and the extended lifespan (Fig. 5K) of CTLA-4
Fig. 4. Bcr-Abl elevates integrin-mediated cell adhesion in a K3-dependent manner. (A) Protein expression of Bcr-Abl, c-Abl, murine K3, human K3 (rescue),
and GAPDH by 32D myeloblasts with or without Bcr-Abl expression (BA+ or BA−), with or without Fermt3 gene deletion (K3+ or K3−), and with or without
human K3 reexpression (rescue). (B) 32D cell adhesion to FN (n = 9), VCAM-1 (n = 6), or ICAM-1 (n ≥ 9) under static conditions. (C) 32D cells stably adhering to
FN or VCAM-1 under flow (n ≥ 7). (D) 32D cell chemotaxis toward CXCL12 with or without preincubation with imatinib overnight (n ≥ 6). (E) 9EG7 staining
intensities in 32D cells plated on FN (n ≥ 33) or VCAM-1 (n ≥ 49). Statistics by Kruskal–Wallis test. (F and G) K3 and Talin-1 mRNA (F; n ≥ 9) and Bcr-Abl, c-Abl,
p-CrkL, K3, Talin-1, and GAPDH protein (G; n = 5) expression in 32D cells with or without 24-h imatinib treatment. Data are shown as mean ± SD. Statistics by
one-way ANOVA, Tukey’s multiple-comparison test if not indicated otherwise. *P < 0.05, **P < 0.01, and ***P < 0.001.


































Fig. 5. Depletion of K3 in LSCs with a CTLA-4 RNA aptamer-tagged K3-siRNA. (A) Bcr-Abl, CTLA-4, K3, and GAPDH mRNA levels in LSK cells isolated from the
BM of individual wild-type (BA−K3WT) or leukemic (BA+K3WT) mice. (B) CTLA-4 mRNA levels measured by qPCR. Statistics by Mann–Whitney U test, two-sided.
(C) CTLA-4 surface expression on LSK cells isolated from the BM of BA−K3WT or BA+K3WT mice. (D) CTLA-4 surface expression on HSPC subpopulations isolated
from the BM of BA+K3WT mice. (E and F) Ratio between PB CD45.2+ donor and CD45.1+ host cells (E) and percentage of PB neutrophils of CD45.2+ donor cells
(F) in sublethally irradiated CD45.1+ WT recipients transplanted with 100 CD45.2+ LSK CD150+CD48− CTLA4+ or 100 CD45.2+ LSK CD150+CD48− CTLA-4− cells
isolated from BA+K3WT mice (n ≥ 9). Statistics by two-way ANOVA, Sidak’s multiple-comparison test (E), and multiple t test, two-sided (F). (G) Sequence of the
CTLA-4–targeting RNA aptamer linked to stabilized mK3-siRNA labeled with fluorescein isothiocyanate (FITC). (H) Bright-field images of BM-derived LSK
CD150+ cells from BA−K3WT or BA+K3WT mice stained with FITC-labeled CTLA-4 aptamer. (Scale bars, 10 μm.) Percentages indicate the amount of FITC+ LSK
CD150+ cells determined by flow cytometry (n ≥ 5). (I) K3 mRNA levels of CTLA-4+ LSK cells isolated from CTLA-4 aptamer-tagged scrambled control (scr)- or
mK3-siRNA–treated BA+K3WT mice (n = 4). Statistics by Mann–Whitney U test, two-sided. (J) PB neutrophils of BA+K3WT mice before and after treatment with
CTLA-4 aptamer-tagged scrambled control- or mK3-siRNA (n ≥ 5). Statistics by two-way ANOVA, Sidak’s multiple-comparison test. Data are shown as mean ±
SEM. (K) Kaplan–Meier survival curve of BA+K3WT mice treated with CTLA-4 aptamer-tagged scrambled control- or mK3-siRNA (n ≥ 5). Statistics by log-rank
test. (L) PB neutrophil numbers of CTLA-4 aptamer-tagged scrambled control- or mK3-siRNA–treated BA+K3WT mice suffering from a CML relapse (n = 5).
Statistics by unpaired t test, two-sided. (M) CTLA-4 surface expression on LSK CD150+CD48− cells isolated from the BM of BA+K3WT mice treated with CTLA-4
aptamer tagged-scrambled control- or mK3-siRNA (n ≥ 3). (N and O) Ratio between PB CD45.2+ donor and CD45.1+ host cells (N) and percentage of PB
neutrophils of CD45.2+ donor cells (O) in sublethally irradiated CD45.1+ WT recipients receiving 100 or 400 CD45.2+ LSK CD150+CD48− cells derived from CTLA-
4 aptamer-tagged scrambled control- or mK3-siRNA–treated BA+K3WT mice (n ≥ 8). Statistics by two-way ANOVA, Sidak’s multiple-comparison test (N), and
multiple t test, two-sided (O). Data are shown as mean ± SD if not indicated otherwise. *P < 0.05, **P < 0.01, and ***P < 0.001.



























aptamer-tagged mK3-siRNA–treated BA+K3WT mice strongly
suggest that the treatment targets, mobilizes, and eventually
eradicates disease-initiating LSCs. To test the hypothesis, we first
engrafted 100 CD45.2+ LSK CD150+CD48− cells derived from
the BM of CTLA-4 aptamer-tagged scrambled control- or mK3-
siRNA–treated BA+K3WT mice into sublethally irradiated
CD45.1+ WT recipients and monitored PB donor cell repopu-
lation and CML development. Whereas the LSK CD150+CD48−
cells from scrambled control-siRNA–treated BA+K3WT mice rapidly
engrafted and developed a leukemic neutrophil population in 9 out of
12 recipient mice, the LSK CD150+CD48− cells from mK3-
siRNA–treated BA+K3WT animals showed poor repopulation po-
tential and increased neutrophil numbers in only 1 out of 12 recipient
mice (Fig. 5 N and O). The engraftment potential of 400 CD45.2+
LSK CD150+CD48− cells from mK3-siRNA–treated BA+K3WT
donor mice was comparable to that of 400 LSK CD150+CD48− cells
from scrambled control-siRNA–treated BA+K3WT donor mice.
However, the increase of CD45.2+ leukemic neutrophils in the PB
was only observed when mice received LSK CD150+CD48− cells
from scrambled control-siRNA–treated leukemic BA+K3WT donor
mice (Fig. 5 N and O). The calculation of disease-initiating LSCs
revealed that the BM of BA+K3WT mice treated with CTLA-4
aptamer-tagged scrambled control-siRNA harbored 1 LSC per 71
LSK CD150+CD48− cells, while the BM of BA+K3WT mice treated
with CTLA-4 aptamer-tagged mK3-siRNA harbored 1 LSC per 927
LSK CD150+CD48− cells.
Taken together, our results demonstrate that the in vivo de-
livery of a K3-siRNA via LSC-specific anchors targets and dis-
places disease-initiating LSCs in the BM and halts CML
progression in and extends lifespan of CML mice.
Discussion
A hallmark of hematological malignancies that initiate from
LSCs is the profound remodeling and adaptation of the normal
HSPC BM environment, which reinforces the activity of LSCs
and in the end leads to the displacement of normal hemato-
poiesis (3, 4). Attempts to halt disease progression by releasing
LSCs from their malignant BM microenvironment, however,
have produced conflicting results (47–53). The major drawback
of the approach is relocation of the leukemia from the BM to
secondary organs such as the spleen or central nervous system
(48, 54). Since most blood cells including normal HSPCs require
integrins to extravasate and retain in the BM (28, 55, 56), we
asked whether abrogating K3 expression and thereby abolishing
the activation and function of most if not all integrin classes on
LSCs is sufficient to induce LSC detachment from the BM mi-
croenvironment, prevent their settlement in distant organs, and
protect from leukemia.
We used the inducible double-transgenic Scl-tTA/Tre-Bcr-Abl
(BA+) murine CML model (37) to investigate K3 function(s) in
LSCs and for the course of leukemia. Tamoxifen-induced dele-
tion of K3 followed by inducing the expression of Bcr-Abl in
BA+ mixed BM chimeras produced a rapid release of BA+K3−
HSPCs into the circulation, a delayed increase of neutrophil
counts in the PB, and a significant lifespan extension. The cir-
culating BA+K3− HSPCs were unable to settle in secondary
hematopoietic organs and induce an extramedullary leukemia.
The marked lifespan extension of leukemic mice was apparent
irrespective of whether Bcr-Abl expression was induced before
or after the deletion of Fermt3, indicating that K3 loss curbs both
the development and the progression of CML.
Our findings also indicate that K3 deficiency curbs the deadly
blast-like crisis induced with p210 Bcr-Abl–expressing (BA+)
32D myeloid progenitor cells (40, 57) in syngeneic recipient
mice. The lack of K3 expression reduced peripheral survival,
proliferation, and BM homing of BA+ 32D cells and prolonged
the survival of engrafted mice. K3 loss abolished the Bcr-
Abl–mediated integrin hyperactivity of BA+ 32D cells caused
by up-regulating Talin-1 and K3 mRNA transcription. Inducing
integrin hyperactivity is a subtle and highly efficient strategy of
the Bcr-Abl oncogene to induce remodeling of the BM envi-
ronment and strong adhesion to and retention of LSCs in the
protective microenvironment of the BM and secondary organs,
which eventually results in metastatic leukemia.
The disruptive power of K3 loss on LSCs and the course of
CML identified K3 depletion as a treatment strategy. The vital
role of K3 for several hematopoietic cells including normal
HSPCs (28), however, demanded a delivery system that transfers
an anti-K3 compound such as K3-siRNA into LSCs and yet
avoids normal HSPCs. In our search for such a delivery system,
we discovered that the immune checkpoint receptor CTLA-4 is
expressed on ∼10% of BA+ (LSK CD150+CD48−) HSCs but not
normal (BA−) HSCs, and that the disease-initiating LSCs are
enriched in the CTLA-4+ BA+ HSC population. To exploit
CTLA-4 expression on LSCs for a targeted treatment of leuke-
mic BA+K3WT mice, we fused a CTLA-4–binding RNA-based
aptamer (46) to a stable K3-siRNA. This treatment approach
efficiently depleted K3 in CTLA-4+ BA+ LSK cells, decreased
the disease-initiating LSC numbers in the BM and neutrophil
counts in the PB, prevented LSC dissemination into extra-
medullary organs, prolonged the survival of the CML mice, and,
most impressively, induced long-lasting remissions in mice suf-
fering from CML relapses. Importantly, the CTLA-4 RNA
aptamer by itself showed no obvious side effects such as in-
flammation or T cell activation, which is probably due to the
poor anti–CTLA-4 inhibitory activity of the monomeric form of
the RNA aptamer (46) used in our study.
Transplantation experiments with BA+ LSK CD150+CD48−
cells derived from the BM of CTLA-4 aptamer scrambled control-
siRNA–treated BA+ leukemic mice indicate that the disease-
initiating LSCs are rare and lowered by more than 100-fold
upon CTLA-4 aptamer-tagged K3-siRNA treatment. Our calcu-
lations indicate that the leukemia-initiating capacity is restricted to
∼1% of the BA+ LSK CD150+CD48− cell population, which is in
line with a published study (58), and to ∼10% of CTLA-4+ BA+
LSK CD150+CD48− cells, which suggests that the size of the
CTLA-4+ BA+ LSK CD150+CD48− cell population exceeds the
number of CTLA-4+ disease-initiating BA+ LSCs. It is conceiv-
able, therefore, that BA+ LSK CD150+CD48− cells acquire mu-
tations that induce the expression of CTLA-4 before a mutation(s)
arises that cooperates with Bcr-Abl to generate disease-initiating
LSCs. If so, dislodging the entire pool of CTLA-4+ BA+ LSK
CD150+CD48− cells from the BM environment might eliminate
not only disease-initiating LSCs but also their premalignant
progenitors.
Inspection of the published literature revealed that also a CML
patient-derived CD34+ BM cell population expresses CTLA-4
(59). Unfortunately, this CTLA-4+ cell population was not further
characterized, and therefore it is not possible to deduce from these
data whether the human disease-initiating LSCs are, like in the
mouse, enriched in this CTLA-4+ BM cell population. Clearly, the
CTLA-4 aptamer also binds to human CTLA-4 (60) and effi-
ciently delivers a stable human K3-siRNA into activated T cells,
decreasing K3 mRNA expression. These findings highlight the
principal feasibility of our approach in the human system and call
for trials in a humanized mouse model.
Materials and Methods
Detailed descriptions are provided in SI Appendix.
Experimental Models.
Mice. CML was induced in mice carrying the Scl-tTA and Tre-Bcr-Abl (BAcond)
transgenes and blocked by tetracycline administration via drinking water
(0.5 g/L; bela-pharm) (37). K3flox/flox Rosa26Cre-ERT2 (K3cond) mice have been
described (28). These mice were backcrossed and kept on a C57BL/6 back-
ground. C3H/HeOuJ mice were obtained from Charles River. Mice were kept


































under specific pathogen-free conditions in the animal facility of the Max
Planck Institute of Biochemistry. The mouse experiments were approved by
the Government of Upper Bavaria.
Cell lines. All cell lines were cultured at 37 °C and 5% CO2. All cell lines were
routinely screened for mycoplasma contamination by PCR-based screenings
(PCR Mycoplasma Test Kit II; PanReac AppliChem) following the instructions
of the manufacturer. Cell lines were routinely characterized by surface
marker expression using flow cytometry.
32D cells (clone 3, mouse, ACC-411; DSMZ) were cultured in Roswell Park
Memorial Institute (RPMI) 1640 medium (Gibco) supplemented with 10% fetal
calf serum (FCS), 10% preconditioned supernatant of Wehi-3B cell (mouse,
ACC-26; DSMZ) cultures, glutamine, and antibiotics. Wehi-3B cells were cul-
tured in RPMI-1640 supplemented with 10% FCS, glutamine, and antibiotics.
Quantification and Statistical Analysis. Statistical analysis was performed with
GraphPad Prism 6. For every reported dataset at least two independent ex-
periments were performed. All datasets were tested for normal distribution.
Statistical significance was assumed at P < 0.05. *P < 0.05, **P < 0.01, and
***P < 0.001. Statistical tests used for the experiments are described in the
figure legends. Unless otherwise noted, all values are reported as mean ± SD.
Data Availability. We confirm that the data supporting the findings of this
study are available within the article and SI Appendix or in public resources
(Microarray Innovations in Leukemia Study; National Center for Biotech-
nology Information Gene Expression Omnibus [GSE13159]).
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